Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
Public ClinicalTrials.gov record NCT00716066. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.
Study identification
- NCT ID
- NCT00716066
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 53 participants
Conditions and interventions
Conditions
- Autoimmune Disease
- Neurologic Autoimmune Disease
- Autologous Transplant Autoimmune
- Multiple Sclerosis Transplant
- MS Stem Cell Transplant
- Multiple Sclerosis Stem Cell Transplant
- Stiff Person Syndrome
- HCT for Neurologic Autoimmune Disorders
- CIDP Transplant
- Myasthenia Gravis Transplant
- Autoimmune Nervous System Disorder
- Central Nervous System Vasculitis
- Cerebellar Degeneration
- Chronic Inflammatory Demyelinating Polyneuropathy
- Lambert Eaton Myasthenic Syndrome
- Myasthenia Gravis
- Neuromyelitis Optica
- Opsoclonus Myoclonus Syndrome
- Rasmussen Subacute Encephalitis
Interventions
- Anti-Thymocyte Globulin Biological
- Autologous Hematopoietic Stem Cell Transplantation Procedure
- Carmustine Drug
- Cytarabine Drug
- Etoposide Drug
- Laboratory Biomarker Analysis Other
- Melphalan Drug
- Peripheral Blood Stem Cell Transplantation Procedure
- Prednisone Drug
- Syngeneic Bone Marrow Transplantation Procedure
Biological · Procedure · Drug + 1 more
Eligibility (public fields only)
- Age range
- Up to 71 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2008
- Primary completion
- Dec 29, 2025
- Completion
- Jan 30, 2030
- Last update posted
- Feb 26, 2026
2008 – 2030
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
| Swedish Medical Center-First Hill | Seattle | Washington | 98122-4307 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00716066, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 26, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00716066 live on ClinicalTrials.gov.